CRISPR Therapeutics AG (CRSP)
53.73
-1.92
(-3.45%)
USD |
NASDAQ |
Apr 25, 16:00
54.39
+0.66
(+1.23%)
After-Hours: 20:00
CRISPR Therapeutics Total Liabilities (Quarterly): 346.77M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 346.77M |
| September 30, 2023 | 359.04M |
| June 30, 2023 | 380.99M |
| March 31, 2023 | 389.47M |
| December 31, 2022 | 367.58M |
| September 30, 2022 | 399.40M |
| June 30, 2022 | 372.53M |
| March 31, 2022 | 361.26M |
| December 31, 2021 | 352.42M |
| September 30, 2021 | 308.80M |
| June 30, 2021 | 295.72M |
| March 31, 2021 | 152.41M |
| December 31, 2020 | 163.73M |
| September 30, 2020 | 141.72M |
| June 30, 2020 | 135.86M |
| March 31, 2020 | 121.20M |
| Date | Value |
|---|---|
| December 31, 2019 | 127.33M |
| September 30, 2019 | 128.71M |
| June 30, 2019 | 126.56M |
| March 31, 2019 | 118.06M |
| December 31, 2018 | 96.82M |
| September 30, 2018 | 101.59M |
| June 30, 2018 | 87.98M |
| March 31, 2018 | 84.12M |
| December 31, 2017 | 83.51M |
| September 30, 2017 | 103.36M |
| June 30, 2017 | 107.17M |
| March 31, 2017 | 107.17M |
| December 31, 2016 | 112.12M |
| September 30, 2016 | 341.18M |
| June 30, 2016 | 157.72M |
| December 31, 2015 | 188.55M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
121.20M
Minimum
Mar 2020
399.40M
Maximum
Sep 2022
264.82M
Average
308.80M
Median
Sep 2021
Total Liabilities (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | 5.150B |
| Intellia Therapeutics Inc | 250.81M |
| Novartis AG | 54.58B |
| Verve Therapeutics Inc | 153.19M |
| AC Immune SA | 26.40M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 2.230B |
| Shareholders Equity (Quarterly) | 1.883B |
| Current Ratio | 17.54 |